Effect of Oxybutynin on Opioid Use After Urologic Surgery in Children
Condition(s) studied
Investigational drug(s) / intervention(s)
Oxybutynin: Participants will receive oxybutynin 0.2 mg/kg (to a maximum dose of 5 mg), orally administered by the day surgery nurse in the day surgery holding area prior to surgery.
Placebo: Participants will receive a matching placebo tablet, orally administered by the day surgery nurse in the day surgery holding area prior to surgery.
Study summary
The goal of this clinical trial is to determine whether giving oxybutynin before urologic reconstruction surgery reduces the amount of opioid pain medication needed in children. Oxybutynin is a medication that helps reduce bladder spasms, which can cause pain and discomfort after surgery.
The main question this study aims to answer is:
Does giving oxybutynin before surgery reduce the amount of opioid pain medication children need during the first 6 hours after surgery?
Researchers will compare oxybutynin with a placebo (a tablet containing no active medication) to see whether oxybutynin reduces opioid use after surgery.
Eligibility
Primary outcome measure(s)
- Total Cumulative Postoperative Opioid Consumption (MME/kg) — From the end of surgery through 6 hours postoperatively
Total cumulative morphine milligram equivalents per kilogram (MME/kg) administered within 6 hours after surgery
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Alberta Children's Hospital | Calgary | Alberta |
More University of Calgary trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07911137 on ClinicalTrials.gov ↗ ← All trials in Canada